Stock IMU IMUGENE LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Imugene Limited

Equities

IMU

AU000000IMU9

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 02:10:44 2024-04-26 am EDT 		5-day change 1st Jan Change
0.079 AUD -4.82% Intraday chart for Imugene Limited +11.27% -28.18%
Apr. 16 Imugene Signs Deal to Sell Manufacturing Facility For $6 Million MT
Apr. 16 Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited for $6 million. CI

Valuation

Fiscal Period: Juni 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 57.76 137.2 1,762 1,056 584.5 578.3 - -
Enterprise Value (EV) 1 38.71 137.2 1,762 1,056 584.5 578.3 578.3 578.3
P/E ratio -7.27 x -11.9 x -88.8 x -26.9 x -14.7 x -4.23 x -6.08 x -9.88 x
Yield - - - - - - - -
Capitalization / Revenue 14 x 32.6 x - - - - - 13.2 x
EV / Revenue 14 x 32.6 x - - - - - 13.2 x
EV / EBITDA -7.11 x - -107 x - -11.9 x -6.16 x -9.97 x -16.4 x
EV / FCF - -13.1 x -131 x -33.9 x -18.6 x -6.79 x -10.8 x -16.8 x
FCF Yield - -7.61% -0.76% -2.95% -5.38% -14.7% -9.27% -5.95%
Price to Book - 2.29 x 27.1 x 7.63 x 3.11 x 3.95 x 5.64 x 9.88 x
Nbr of stocks (in thousands) 3,609,848 4,425,971 4,962,842 5,865,700 6,423,039 7,319,811 - -
Reference price 2 0.0160 0.0310 0.3550 0.1800 0.0910 0.0790 0.0790 0.0790
Announcement Date 8/30/19 8/31/20 8/30/21 8/30/22 8/25/23 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Juni 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 4.127 4.21 - - - - - 43.78
EBITDA 1 -8.121 - -16.5 - -49.09 -93.8 -58 -35.3
EBIT 1 -8.184 -10.81 -18.47 -37.94 -41.02 -131.9 -116.1 -81.54
Operating Margin -198.29% -256.67% - - - - - -186.22%
Earnings before Tax (EBT) 1 -7.775 -10.51 -18.46 -37.87 -39.17 -118.1 -100.3 -68.87
Net income 1 -7.775 -10.51 -18.46 -37.87 -39.17 -116 -100.3 -68.87
Net margin -188.39% -249.61% - - - - - -157.3%
EPS 2 -0.002200 -0.002600 -0.004000 -0.006700 -0.006200 -0.0187 -0.0130 -0.008000
Free Cash Flow 1 - -10.44 -13.42 -31.11 -31.47 -85.2 -53.6 -34.4
FCF margin - -248.06% - - - - - -78.57%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 8/30/19 8/31/20 8/30/21 8/30/22 8/25/23 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2 2025 S1 2025 S2
Net sales 1 - 1.835 - - - - - - - - - -
EBITDA 1 - - - - - - - - - -41.8 - -
EBIT 1 - -5.907 -6.04 -12.43 -15.21 -22.73 -17.87 -23.15 -71.01 -52.02 -61.2 -63.34
Operating Margin - -321.91% - - - - - - - - - -
Earnings before Tax (EBT) 1 - - -6.063 -12.39 -14.83 -23.04 -17.39 -21.78 -68.71 -52.25 -51.8 -52.94
Net income 1 -4.791 - -6.063 -12.39 -14.83 -23.04 -17.39 -21.78 -68.71 -52.25 -51.8 -52.94
Net margin - - - - - - - - - - - -
EPS 2 -0.001300 - -0.001300 -0.002700 -0.002700 -0.004000 -0.002800 -0.003400 -0.0100 -0.0100 -0.0100 -0.0100
Dividend per Share - - - - - - - - - - - -
Announcement Date 2/26/20 8/31/20 2/26/21 8/30/21 2/27/22 8/30/22 2/28/23 8/25/23 2/28/24 - - -
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position 19 - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - -10.4 -13.4 -31.1 -31.5 -85.2 -53.6 -34.4
ROE (net income / shareholders' equity) - -24.1% -29.6% -37.2% -24% -66% -61% -66%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - 0.0100 0.0100 0.0200 0.0300 0.0200 0.0100 0.0100
Cash Flow per Share - - - - - - - -
Capex 0.13 - - - - - - -
Capex / Sales 3.11% - - - - - - -
Announcement Date 8/30/19 8/31/20 8/30/21 8/30/22 8/25/23 - - -
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.079 AUD
Average target price
0.3533 AUD
Spread / Average Target
+347.25%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IMUGENE LIMITED Stock Imugene Limited
-28.18% 377M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IMU Stock
  4. Financials Imugene Limited